Equity Overview
Price & Market Data
Price: $1.73
Daily Change: -$0.08 / 4.62%
Daily Range: $1.70 - $1.88
Market Cap: $66,845,092
Daily Volume: 69,827
Performance Metrics
1 Week: -18.40%
1 Month: -23.79%
3 Months: 47.86%
6 Months: 92.22%
1 Year: 40.09%
YTD: 44.17%
Details
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.